Today, the Food and Drug Administration approved Opill – the first-ever daily oral contraceptive approved in the U.S. to prevent pregnancy without a prescription. Perrigo, which sought FDA approval for an over-the-counter version last summer after the Supreme Court's ruling the overturned Roe v. Wade, expects to start shipping the mini pill early next year.
In May, Ireland-based Perrigo, a leading provider of consumer self-care products, gained a key recommendation from U.S. regulatory advisors, which paved the way for Opill to get clearance to be sold without a prescription. The FDA is not required to follow the advisers' recommendations, but often does.
The American Medical Association and the leading professional society for obstetricians and gynecologists backed Opill's application for over-the-counter status.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
